Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    22939997 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma
Condition: Cholangiocarcinoma
Intervention: Drug: Nab-Paclitaxel and Gemcitabine

Indicates status has not been verified in more than two years